CD4+CD25+FOXP3+ regulatory T cells to protect against graft-versus-host disease.

CD4+CD25+FOXP3+ regulatory T cells significantly reduce graft-versus-host disease risk in allogeneic hematopoietic cell transplantation.

• Why it matters: Graft-versus-host disease (GVHD) and immune failure are major obstacles limiting the broader application of HCT, especially for high-risk patients, due to high non-relapse mortality.
• What they did: The study reviews the history, preclinical research, and successful clinical translation of CD4+CD25+FOXP3+ regulatory T cells (Treg) as a strategy to improve transplant outcomes.
• The result: Harnessing Treg cells offers a promising approach to mitigate GVHD, potentially enabling safer transplants and expanding treatment options for immune-mediated disorders.